Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerations
Latest Information Update: 03 Jan 2022
At a glance
- Drugs Voretigene neparvovec (Primary)
- Indications Retinal degeneration
- Focus Therapeutic Use
- Acronyms Luxturna follow-up
- 03 Feb 2021 New trial record